MX2015013059A - Sales, co-cristales, y polimorfos de un compuesto ansiolitico. - Google Patents
Sales, co-cristales, y polimorfos de un compuesto ansiolitico.Info
- Publication number
- MX2015013059A MX2015013059A MX2015013059A MX2015013059A MX2015013059A MX 2015013059 A MX2015013059 A MX 2015013059A MX 2015013059 A MX2015013059 A MX 2015013059A MX 2015013059 A MX2015013059 A MX 2015013059A MX 2015013059 A MX2015013059 A MX 2015013059A
- Authority
- MX
- Mexico
- Prior art keywords
- crystals
- salts
- polymorphs
- compound
- pharmaceutical compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/10—Succinic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención proporciona formas amorfas y cristalinas de 1-etil-6-(indan-2-ilamino)-3-(morfolin-4-carbonil)-1, 8-naftiridin-4-ona (compuesto 1), y sales, co-cristales, y composiciones farmacéuticas de las mismas. La invención también proporciona métodos para el tratamiento de y/o la prevención de una enfermedad, tal como una enfermedad del sistema nervioso central (por ejemplo, un trastorno de ansiedad), utilizando las formas amorfas y cristalinas, y sales, co-cristales, y composiciones farmacéuticas de las mismas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361798926P | 2013-03-15 | 2013-03-15 | |
PCT/AU2014/000272 WO2014138812A1 (en) | 2013-03-15 | 2014-03-14 | Salts, co-crystals, and polymorphs of an anxiolytic compound |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2015013059A true MX2015013059A (es) | 2016-08-05 |
Family
ID=51535621
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015013059A MX2015013059A (es) | 2013-03-15 | 2014-03-14 | Sales, co-cristales, y polimorfos de un compuesto ansiolitico. |
Country Status (9)
Country | Link |
---|---|
US (2) | US9745296B2 (es) |
EP (1) | EP2970247A4 (es) |
JP (1) | JP2016510768A (es) |
CN (1) | CN105492440A (es) |
AU (2) | AU2014231722B2 (es) |
CA (1) | CA2905570A1 (es) |
HK (1) | HK1220191A1 (es) |
MX (1) | MX2015013059A (es) |
WO (1) | WO2014138812A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6688434B2 (en) | 2002-02-22 | 2004-02-10 | Ecolab Inc. | Conveyor and lubricating apparatus, lubricant dispensing device, and method for applying lubricant to conveyor |
CN105541701A (zh) * | 2015-12-11 | 2016-05-04 | 吉林大学珠海学院 | 以顺丁烯二酸为前驱体的去铁酮药物共晶及其制备方法 |
TWI729049B (zh) * | 2015-12-15 | 2021-06-01 | 以色列商諾發測量儀器股份有限公司 | 圖案化結構中基於拉曼光譜之測量 |
WO2019109150A1 (en) * | 2017-12-07 | 2019-06-13 | Bionomics Limited | Methods of treating agitation |
US20230147869A1 (en) * | 2019-09-23 | 2023-05-11 | Bionomics Limited | Therapeutic formulations and uses thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005018565A2 (en) * | 2003-08-21 | 2005-03-03 | Transoral Pharmaceuticals, Inc. | Compositions for delivering 5-ht agonists across the oral mucosa and methods of use thereof |
WO2008046135A1 (en) * | 2006-10-16 | 2008-04-24 | Bionomics Limited | Novel anxiolytic compounds |
DE102006060598A1 (de) * | 2006-12-21 | 2008-06-26 | Merck Patent Gmbh | Tetrahydrobenzoisoxazole |
GB0706044D0 (en) * | 2007-03-28 | 2007-05-09 | Syngenta Ltd | C0-Crystals |
CA2781182A1 (en) * | 2009-12-03 | 2011-06-09 | Astrazeneca Ab | Co - crystals of a triazolo [4,5 - d] pyrimidine platelet aggregation inhibitor |
US20140051701A1 (en) * | 2011-03-02 | 2014-02-20 | Bionomics Limited | Methods of treating a disease or condition of the central nervous system |
WO2012151640A1 (en) * | 2011-05-12 | 2012-11-15 | Bionomics Limited | Methods for preparing naphthyridines |
AU2013204159B2 (en) * | 2013-03-15 | 2015-05-07 | Bionomics Limited | A Crystalline Form of an Anxiolytic Compound |
-
2014
- 2014-03-14 CA CA2905570A patent/CA2905570A1/en not_active Abandoned
- 2014-03-14 CN CN201480028564.4A patent/CN105492440A/zh active Pending
- 2014-03-14 US US14/776,643 patent/US9745296B2/en active Active
- 2014-03-14 JP JP2015561831A patent/JP2016510768A/ja active Pending
- 2014-03-14 AU AU2014231722A patent/AU2014231722B2/en active Active
- 2014-03-14 WO PCT/AU2014/000272 patent/WO2014138812A1/en active Application Filing
- 2014-03-14 MX MX2015013059A patent/MX2015013059A/es unknown
- 2014-03-14 EP EP14765186.3A patent/EP2970247A4/en not_active Withdrawn
-
2016
- 2016-07-14 HK HK16108260.8A patent/HK1220191A1/zh unknown
-
2017
- 2017-03-21 AU AU2017201916A patent/AU2017201916B2/en active Active
- 2017-08-25 US US15/687,274 patent/US10266529B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN105492440A (zh) | 2016-04-13 |
HK1220191A1 (zh) | 2017-04-28 |
CA2905570A1 (en) | 2014-09-18 |
US10266529B2 (en) | 2019-04-23 |
EP2970247A4 (en) | 2016-08-10 |
US9745296B2 (en) | 2017-08-29 |
US20170362230A1 (en) | 2017-12-21 |
US20160185770A1 (en) | 2016-06-30 |
EP2970247A1 (en) | 2016-01-20 |
AU2014231722B2 (en) | 2016-12-22 |
AU2014231722A1 (en) | 2015-09-24 |
JP2016510768A (ja) | 2016-04-11 |
AU2017201916B2 (en) | 2018-09-27 |
AU2017201916A1 (en) | 2017-04-13 |
WO2014138812A1 (en) | 2014-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018502102A1 (en) | Pyrrolotriazine compounds as tam inhibitors | |
PH12016502382A1 (en) | Substituted indazole compounds as irak4 inhibitors | |
PH12019501321A1 (en) | Methods of treating or preventing cholesterol related disorders | |
CL2015002529A1 (es) | Compuestos de tetrahidropirrolotiazina | |
MX2018000396A (es) | Compuestos aza sustituidos como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak-4). | |
EA201791305A1 (ru) | Конденсированные пиримидины для лечения вич | |
WO2016130920A3 (en) | Lrrk2 inhibitors and methods of making and using the same | |
MX2016009403A (es) | Compuestos heterociclicos. | |
PH12015502502A1 (en) | Heteroaromatic compounds and their use as dopamine d1 ligands | |
TN2015000018A1 (en) | 5-ht3 receptor antagonists | |
TN2018000020A1 (en) | Colony stimulating factor-1 receptor (csf-1r) inhibitors. | |
EA201400624A1 (ru) | Замещенные 4-фенилпиридины для лечения болезней, связанных с рецептором nk-1 | |
TN2017000075A1 (en) | Compounds and compositions as raf kinase inhibitors | |
PH12017500920A1 (en) | 4-oxo-3,4-dihydro-1,2,3-benzotriazine as modulators of gpr139 | |
PH12016501624A1 (en) | 1,2-substituted cyclopentanes as orexin receptor antagonists | |
MX2015013059A (es) | Sales, co-cristales, y polimorfos de un compuesto ansiolitico. | |
NZ728707A (en) | 2’-chloro aminopyrimidinone and pyrimidine dione nucleosides | |
MX2016008898A (es) | Antagonistas selectivos de nr2b. | |
MY192609A (en) | Substituted bicyclic heteroaryl compounds as rxr agonists | |
MX369451B (es) | Formas cristalinas de compuestos basados en 1, 8- naftiridin-4(h)-ona particulares y su uso en el tratamiento de ansiedad y condiciones relacionadas. | |
SG10201810263QA (en) | Nampt inhibitors and methods | |
EA201791450A1 (ru) | 3,5-диаминопиразоловые ингибиторы киназы | |
PH12017500492A1 (en) | Crystalline bace inhibitors | |
NZ748942A (en) | Pyrazolylaminobenzimidazole derivatives as jak inhibitors | |
MX2016015959A (es) | Derivados de carbamato los cuales son tanto inhibidores de la enzima fosfodiesterasa 4 (pde4) como antagonistas del receptor muscarinico m3. |